2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases

This Broad Agency Announcement (BAA) from the National Institutes of Health seeks proposals to develop medical countermeasures—vaccines, therapeutics, and rapid diagnostics—against high‑priority infectious disease threats. Offerors may compete in any of three research areas, each requiring pre‑clinical work, IND‑enabling studies, GMP‑grade material, and a Phase I (or early Phase II) clinical trial component. The solicitation is cost‑reimbursement, up to $16 million total FY 27 funding for up to four contracts, with a maximum performance period of five years. • Research Area 001 – Needle‑free vaccine candidates targeting viral pathogens, requiring IND‑enabling data, GMP manufacturing, and Phase I/early Phase II trial. • Research Area 002 – Novel therapeutic candidates (small molecules, peptides ≤ 40 aa, antibodies, nanobodies, microbiome‑based, bacteriophages) for serious or drug‑resistant infections, with IND‑enabling, GMP, and Phase I (or proof‑of‑concept Phase II) trials. • Research Area 003 – Rapid (<2 hr) sample‑to‑answer in‑vitro diagnostic platforms capable of detecting a broad panel of priority viral families, with high analytical sensitivity and point‑of‑care automation. Proposals must be submitted electronically via NIH eCPS by 3 PM EST on 8 Dec 2026, include detailed technical data (structures, potency, ADMET, efficacy, PK, toxicology) and comply with extensive regulatory, human‑subjects, animal‑welfare, and data‑sharing requirements.